Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram ...

Alterity Therapeutics Limited (ASX:ATH), a pharmaceutical company specializing in the development of therapeutic drugs with a market capitalization of $26.89 million, has filed its quarterly ...

The company formerly known as Athletic Greens is expanding its market beyond the self-optimizers that follow the podcasters ...